4-甲基-2-[4-(三氟甲基)苯基]-1,3-噻唑-5-甲醛 | 438577-61-8

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-甲基-2-[4-(三氟甲基)苯基]-1,3-噻唑-5-甲醛
• 英文名称: 4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazole-5-carbaldehyde
• 英文别名: 4-methyl-2-(4-trifluoromethylphenyl)-1,3-thiazole-5-carboxaldehyde；4-methyl-2-(4-trifluoromethylphenyl)-thiazole-5-carboxaldehyde；4-methyl-2-(4-(trifluoromethyl)phenyl)thiazole-5-carbaldehyde
• CAS: 438577-61-8
• 化学式: C₁₂H₈F₃NOS
• 分子量: 271.263
• InChiKey: TULJSSOBHAIERD-UHFFFAOYSA-N

物化性质

• 熔点：
  114-115°C

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  58.2
• 氢给体数：
  0
• 氢受体数：
  6

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2934100090

SDS

Name:	4-Methyl-2-[4-(trifluoromethyl)phenyl]-1 3-thiazole-5-carbaldehyde Material Safety Data Sheet
Synonym:	None Known
CAS:	438577-61-8

Section 1 - Chemical Product MSDS Name:4-Methyl-2-[4-(trifluoromethyl)phenyl]-1 3-thiazole-5-carbaldehyde Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
438577-61-8	4-Methyl-2-[4-(trifluoromethyl)phenyl]	97+	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up or absorb material, then place into a suitable clean, dry, closed container for disposal. Avoid generating dusty conditions. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances. Store under an inert atmosphere.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 438577-61-8: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: brown
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 132.5-135.5 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C12H8F3NOS
Molecular Weight: 271.28

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Dust generation, excess heat.
Incompatibilities with Other Materials:
Amines, oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, oxides of sulfur, carbon dioxide, hydrogen fluoride gas.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 438577-61-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazole-5-carbaldehyde - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing group:

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 6 Keep under nitrogen.
S 22 Do not breathe dust.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 438577-61-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 438577-61-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 438577-61-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-甲基-2-[4-(三氟甲基)苯基]-1,3-噻唑-5-甲醛 在 palladium on activated charcoal 氢气 、 三溴化硼 、 sodium hydride 、 溶剂黄146 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 96.5h， 生成 4-(2-{4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}ethyl)phenol
  参考文献：
  名称：

  Substituted 2-[(4-Aminomethyl)phenoxy]-2-methylpropionic Acid PPARα Agonists. 1. Discovery of a Novel Series of Potent HDLc Raising Agents

  摘要：

  The peroxisome proliferator activated receptors PPAR alpha, PPAR gamma, and PPAR delta are ligand-activated transcription factors that play a key role in lipid homeostasis. The fibrates raise circulating levels of high-density lipoprotein cholesterol and lower levels of triglycerides in part through their activity as PPAR alpha agonists; however, the low potency and restricted selectivity of the fibrates may limit their efficacy, and it would be desirable to develop more potent and selective PPAR alpha agonists. Modification of the selective PPAR delta agonist 1 (GW501516) so as to incorporate the 2-aryl-2-methylpropionic acid group of the fibrates led to a marked shift in potency and selectivity toward PPAR alpha agonism. Optimization of the series gave 25a, which shows EC50 = 4 nM on PPAR alpha and at least 500-fold selectivity versus PPAR delta and PPAR gamma. Compound 25a (GW590735) has been progressed to clinical trials for the treatment of diseases of lipid imbalance.

  DOI：

  10.1021/jm058056x
• 作为产物：
  描述：

  4-(三氟甲基)硫代苯甲酰胺 在 lithium aluminium tetrahydride 、 戴斯-马丁氧化剂 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 7.0h， 生成 4-甲基-2-[4-(三氟甲基)苯基]-1,3-噻唑-5-甲醛
  参考文献：
  名称：

  噻唑连接的查耳酮及其嘧啶类似物作为抗癌剂的合成

  摘要：

  （2021年）。噻唑连接的查耳酮及其嘧啶类似物作为抗癌剂的合成。综合通信：第一卷。51，第9号，第1406-1416页。

  DOI：

  10.1080/00397911.2021.1884262

文献信息

• [EN] 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS<br/>[FR] DERIVES DE PIPERIDINE 1,4 DISUBSTITUEE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE 11-BETAHSD1
  申请人：ASTRAZENECA AB

  公开号：WO2004033427A1

  公开（公告）日：2004-04-22

  The use of a compound of formula (I) in the manufacture of a medicament for use in the inhibition of 11βHSD1 is described.

  使用式(I)的化合物制造用于抑制11βHSD1的药物。
• [EN] AMINOPHENYLCYCLOPROPYL CARBOXYLIC ACIDS AND DERIVATIVES AS AGONISTS TO GPR40<br/>[FR] ACIDES AMINOPHENYLCYCLOPROPYLCARBOXYLIQUES ET LEURS DERIVES SERVANT D'AGONISTES DE GPR40
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2005051890A1

  公开（公告）日：2005-06-09

  The present invention relates generally to novel therapeutic compounds and more particularly to novel compounds, their use as GPR40 agonists, processes for their manufacture, and intermediates useful in their preparation.

  本发明一般涉及新型治疗化合物，更具体地涉及新型化合物，它们作为GPR40激动剂的用途，它们的制造工艺以及在它们的制备中有用的中间体。
• Thiazolyl-indole derivatives, their manufacture and use as pharmaceutical agents
  申请人：Ackermann Jean

  公开号：US20050004187A1

  公开（公告）日：2005-01-06

  This invention relates to compounds of the formula wherein one of R 6 , R 7 or R 8 is and all enantiomers and pharmaceutically acceptable salts and/or esters thereof as well as pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by PPARδ and/or PPARα agonists.

  这项发明涉及以下式的化合物 其中R 6 、R 7 或R 8 中的一个是 以及所有的对映体和药学上可接受的盐和/或酯，以及含有这种化合物的药物组合物，以及它们的制备方法和它们用于治疗和/或预防由PPARδ和/或PPARα激动剂调节的疾病。
• Thia-and oxazoles and their use as ppars activators
  申请人：——

  公开号：US20040102493A1

  公开（公告）日：2004-05-27

  A compound of formula (I) or pharmaceutically acceptable salts and solvates thereof. R 1 and R 2 are independently H or C 1-3 alkyl, m is 0-3; X 1 is NH, NCH 3 , O, S; R 3 , R 4 and R 5 are independently H, CH 3 , CF 3 , OCH 3 , allyl or halogen; X 2 is (CR 10 R 11 )n wherein n is 1 or 2; R 10 and R 11 independently represent H, fluorine or C 1-16 alkyl; R 26 and R 27 are independently H, C 1-3 alkyl or R 26 and R 27 together with the carbon atom to which they are bonded form a 3-5 membered cycloalklyl ring. R 6 and R 7 independently represent H, fluorine or C 1-16 alkyl; R 9 is C 1-6 alkyl or CF 3 ; One of Y and Z is N, the other is S or O; Each R 8 independently represents CF 3 , OCH 3 , CH 3 or halogen; y is O, 1, 2, 3, 4, 5. Use of a compound of formula (I) for the manufacture of a medicament for the prevention or treatment of a hPPAR mediated disease or condition, such as dyslipidemia, syndrome X, heart failure, hypercholesteremia, cardiovascular disease, type II diabetes mellitus, type 1 diabetes, insulin resistance hyperlipidemia, obesity, anorexia bulimia, inflammation and anorexia nervosa. 1

  一种具有化学式（I）或其药学上可接受的盐和溶剂的化合物。R1和R2独立地表示H或C1-3烷基，m为0-3；X1为NH、NCH3、O、S；R3、R4和R5独立地表示H、CH3、CF3、OCH3、烯丙基或卤素；X2为（CR10R11）n，其中n为1或2；R10和R11独立地表示H、氟或C1-16烷基；R26和R27独立地表示H、C1-3烷基或R26和R27与它们结合的碳原子一起形成3-5环的环烷基环。R6和R7独立地表示H、氟或C1-16烷基；R9为C1-6烷基或CF3；Y和Z中的一个为N，另一个为S或O；每个R8独立地表示CF3、OCH3、CH3或卤素；y为O、1、2、3、4、5。使用具有化学式（I）的化合物制备用于预防或治疗hPPAR介导的疾病或症状的药物，例如脂质代谢异常、X综合征、心力衰竭、高胆固醇血症、心血管疾病、2型糖尿病、1型糖尿病、胰岛素抵抗性高脂血症、肥胖、厌食症、炎症和神经性厌食症。
• [EN] NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMA AGONISTS<br/>[FR] NOUVEAUX COMPOSES 2-ARYLTHIAZOLE UTILISES COMME AGONISTES DES RECEPTEURS PPARALPHA ET PPARGAMMA
  申请人：HOFFMANN LA ROCHE

  公开号：WO2004020420A1

  公开（公告）日：2004-03-11

  The present invention relates to compounds of formula (I) wherein Rl to R10, X, Y and n are as defined in the description and claims, and pharmaceutically acceptable salts and esters thereof. The compounds are useful for the treatment of diseases such as diabetes.

  本发明涉及式(I)的化合物，其中R1至R10、X、Y和n如描述和权利要求中所定义，并且其药学上可接受的盐和酯。这些化合物对于治疗疾病如糖尿病是有用的。